Literature DB >> 16054454

Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.

Muzahir H Tayebjee1, Gregory Y H Lip, Kiat T Tan, Jeetesh V Patel, Elizabeth A Hughes, Robert J MacFadyen.   

Abstract

Endogenous matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitor of metalloproteinases (TIMPs), are important mediators of extracellular matrix remodeling, which is integral to plaque progression in coronary artery disease. In addition, high levels of the soluble fragment of CD40 ligand (sCD40L) have previously been associated with adverse cardiovascular outcomes. We hypothesized that circulating levels of MMP-9, TIMP-1, TIMP-2, and sCD40L were abnormal in patients who had stable coronary artery disease, and these levels were compared with those in matched controls. We also hypothesized correlations of MMPs, TIMPs, and sCD40L to each other and to high-sensitivity C-reactive protein (a proinflammatory marker), white blood cell count, severity of coronary artery disease (based on angiographic measurements of atherosclerotic burden), and coronary collateralization. We studied 204 adult patients who attended our unit for outpatient diagnostic cardiac catheterization for the investigation of suspected coronary artery disease. Coronary angiograms were scored for atheroma burden and stenosis by 2 independent observers. Circulating levels of MMP-9, TIMP-1, TIMP-2, and sCD40L were measured by enzyme-linked immunosorbent assay. Plasma levels of MMP-9 (p = 0.0099), TIMP-2 (p = 0.0019), and sCD40L (p <0.001), but not TIMP-1 (p = 0.463) were high in patients compared with healthy controls. In patients who had coronary artery disease, MMP-9 and high-sensitivity C-reactive protein levels were significantly higher in women than in men. Only MMP-9 correlated modestly with total white blood cell count (Spearman's correlation, r = 0.274, p = 0.002). Logistic regression of cardiovascular risk factors showed that only white blood cell count was independently associated with MMP-9 (p = 0.02). After standardizing for atheroma and stenosis scores, there were no statistically significant differences in our research indexes in patients who had angiographic collaterals compared with those who did not. In conclusion, stable coronary artery disease is associated with abnormal circulating levels of MMP-9, TIMP-2, and sCD40L, which do not appear to related to each other or to severity of coronary artery disease or collateralization. The gender difference in high-sensitivity C-reactive protein and MMP-9 levels may provide insight into the pathophysiology of coronary artery disease in men and women, and further studies are warranted to explore this potential link.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054454     DOI: 10.1016/j.amjcard.2005.03.072

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: from the Dallas Heart Study.

Authors:  Justin L Grodin; Tiffany M Powell-Wiley; Colby R Ayers; Darpan S Kumar; Anand Rohatgi; Amit Khera; Darren K McGuire; James A de Lemos; Sandeep R Das
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

2.  Association between arsenic exposure from drinking water and plasma levels of cardiovascular markers.

Authors:  Fen Wu; Farzana Jasmine; Muhammad G Kibriya; Mengling Liu; Oktawia Wójcik; Faruque Parvez; Ronald Rahaman; Shantanu Roy; Rachelle Paul-Brutus; Stephanie Segers; Vesna Slavkovich; Tariqul Islam; Diane Levy; Jacob L Mey; Alexander van Geen; Joseph H Graziano; Habibul Ahsan; Yu Chen
Journal:  Am J Epidemiol       Date:  2012-04-24       Impact factor: 4.897

3.  Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction.

Authors:  Miruna Popa; Sibgha Tahir; Julia Elrod; Su Hwan Kim; Florian Leuschner; Thorsten Kessler; Peter Bugert; Ulrich Pohl; Andreas H Wagner; Markus Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-23       Impact factor: 11.205

Review 4.  Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.

Authors:  Reid G Hendry; Leanne M Bilawchuk; David J Marchant
Journal:  J Cardiovasc Transl Res       Date:  2014-01-01       Impact factor: 4.132

5.  Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals.

Authors:  Lennart Nilsson; Per Eriksson; Pierre Cherfan; Lena Jonasson
Journal:  Inflammation       Date:  2011-08       Impact factor: 4.092

6.  Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain.

Authors:  Chun Gu; Fang Wang; Zhihui Hou; Bin Lv; Yang Wang; Xiangfeng Cong; Xi Chen
Journal:  Heart Vessels       Date:  2017-07-19       Impact factor: 2.037

7.  Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population.

Authors:  Hong Zhi; Hua Wang; Liqun Ren; Zhiyang Shi; Haiyan Peng; Lunbiao Cui; Genshan Ma; Xingzhou Ye; Yi Feng; Chengxing Shen; Xiangjun Zhai; Chenyu Zhang; Ke Zen; Naifeng Liu
Journal:  Mol Biol Rep       Date:  2009-03-13       Impact factor: 2.316

Review 8.  Matrix metalloproteinases and peripheral arterial disease.

Authors:  Chiara Busti; Emanuela Falcinelli; Stefania Momi; Paolo Gresele
Journal:  Intern Emerg Med       Date:  2009-07-21       Impact factor: 3.397

Review 9.  Association of matrix metalloproteinase-9 C1562T polymorphism and coronary artery disease: a meta-analysis.

Authors:  Xiao Wang; Lei-zhi Shi
Journal:  J Zhejiang Univ Sci B       Date:  2014-03       Impact factor: 3.066

10.  MMP-1 serum levels predict coronary atherosclerosis in humans.

Authors:  Michael Lehrke; Martin Greif; Uli C Broedl; Corinna Lebherz; Rüdiger P Laubender; Alexander Becker; Franz von Ziegler; Janine Tittus; Maximilian Reiser; Christoph Becker; Burkhard Göke; Gerhard Steinbeck; Alexander W Leber; Klaus G Parhofer
Journal:  Cardiovasc Diabetol       Date:  2009-09-14       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.